DK2219652T3 - Phospholipidsammensætninger og anvendelser heraf - Google Patents

Phospholipidsammensætninger og anvendelser heraf

Info

Publication number
DK2219652T3
DK2219652T3 DK08852865.8T DK08852865T DK2219652T3 DK 2219652 T3 DK2219652 T3 DK 2219652T3 DK 08852865 T DK08852865 T DK 08852865T DK 2219652 T3 DK2219652 T3 DK 2219652T3
Authority
DK
Denmark
Prior art keywords
lipids
lrh
administration
blood glucose
glucose levels
Prior art date
Application number
DK08852865.8T
Other languages
English (en)
Inventor
David D Moore
Jae Man Lee
Original Assignee
Baylor College Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor College Medicine filed Critical Baylor College Medicine
Application granted granted Critical
Publication of DK2219652T3 publication Critical patent/DK2219652T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/661Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK08852865.8T 2007-11-16 2008-11-17 Phospholipidsammensætninger og anvendelser heraf DK2219652T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98850507P 2007-11-16 2007-11-16
PCT/US2008/012846 WO2009067182A2 (en) 2007-11-16 2008-11-17 Phospholipid compositions and uses thereof

Publications (1)

Publication Number Publication Date
DK2219652T3 true DK2219652T3 (da) 2012-08-06

Family

ID=40668049

Family Applications (1)

Application Number Title Priority Date Filing Date
DK08852865.8T DK2219652T3 (da) 2007-11-16 2008-11-17 Phospholipidsammensætninger og anvendelser heraf

Country Status (7)

Country Link
US (1) US8410085B2 (da)
EP (1) EP2219652B1 (da)
AT (1) ATE554775T1 (da)
AU (1) AU2008326800A1 (da)
CA (1) CA2705530A1 (da)
DK (1) DK2219652T3 (da)
WO (1) WO2009067182A2 (da)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0915523D0 (en) 2009-09-07 2009-10-07 Genome Res Ltd Cells and methods for obtaining them
EP2598125A2 (en) * 2010-05-20 2013-06-05 Fundación Pública Andaluza Progreso Y Salud Novel methods for preventing or treating diabetes
US9512406B2 (en) 2013-12-20 2016-12-06 The J. David Gladstone Institute, a testamentary trust established under the Will of J. David Gladstone Generating hepatocytes
KR20180116275A (ko) 2016-02-22 2018-10-24 노파르티스 아게 Fxr 효능제를 사용하는 방법
KR101865562B1 (ko) * 2017-11-03 2018-06-08 주식회사 펜믹스 포스포콜린 유도체를 포함하는 지방분해 조성물
WO2019244137A1 (en) * 2018-06-22 2019-12-26 Fonterra Co-Operative Group Limited Use of polar lipids to treat or prevent gestational diabetes mellitus
CN115364111B (zh) * 2021-05-17 2024-04-02 中国医学科学院基础医学研究所 甘油磷脂类化合物在治疗肿瘤中的用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5910304A (en) 1982-12-13 1999-06-08 Texas A&M University System Low-dose oral administration of interferons
CA1320905C (en) 1986-11-06 1993-08-03 Joseph M. Cummins Treatment of immuno-resistant disease
WO1997039759A2 (en) 1996-04-24 1997-10-30 Brigham And Women's Hospital Omega-3 fatty acids and omega-3 phosphatidylcholine in the treatment of bipolar disorder
US6036949A (en) 1998-03-05 2000-03-14 Amarillo Biosciences, Inc. Treatment of fibromyalgia with low doses of interferon
US6537806B1 (en) 1998-06-02 2003-03-25 University Of Washington Compositions and methods for treating diabetes
US20030040505A1 (en) 2000-03-31 2003-02-27 The Regents Of The University Of California Synthetic phospholipids to ameliorate atherosclerosis and other inflammatory conditions
GB0014437D0 (en) * 2000-06-14 2000-08-09 Porter William L Immune response stimulation
CA2501601C (en) * 2002-10-25 2008-12-30 Seymour J. Kurtz Method of treating insulin resistance, adult onset diabetes and metabolic syndrome x using small unilamellar vesicles
WO2004108140A1 (en) * 2003-06-05 2004-12-16 Doosan Corporation Composition for inhibiting differentiation or growth of fat cells
JP2007510659A (ja) 2003-11-05 2007-04-26 シェーリング コーポレイション 脂質調節剤および置換アゼチジノンの組み合わせならびに血管状態の処置
US20050255154A1 (en) * 2004-05-11 2005-11-17 Lena Pereswetoff-Morath Method and composition for treating rhinitis
EP1965828A2 (en) * 2005-12-02 2008-09-10 Nastech Pharmaceutical Company Inc. Pharmaceutical formulation for increased epithelial permeability of glucose-regulating peptide

Also Published As

Publication number Publication date
WO2009067182A2 (en) 2009-05-28
WO2009067182A3 (en) 2009-07-23
EP2219652A4 (en) 2010-11-10
US20100331281A1 (en) 2010-12-30
AU2008326800A1 (en) 2009-05-28
US8410085B2 (en) 2013-04-02
EP2219652B1 (en) 2012-04-25
ATE554775T1 (de) 2012-05-15
EP2219652A2 (en) 2010-08-25
CA2705530A1 (en) 2009-05-28

Similar Documents

Publication Publication Date Title
Izzo et al. The role of oxidative stress in cardiovascular aging and cardiovascular diseases
ATE554775T1 (de) Phospholipid-zusammensetzungen und ihre verwendungen
JP2007521835A5 (da)
AU2018253580A1 (en) Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level
WO2010129138A3 (en) Phosphorylated and phosphonated pyrone analogs for therapeutic treatment
WO2008027420A3 (en) Implantable devices for producing insulin
Cavalcanti et al. Administration of reconstituted polyphenol oil bodies efficiently suppresses dendritic cell inflammatory pathways and acute intestinal inflammation
EA201300550A1 (ru) Фармацевтическая композиция, способы лечения и их применение
NO20092150L (no) Fremgangsmater for behandling av hyperkolesterolemi
PE20050255A1 (es) Nuevas cianotiazolidas y procedimiento para su preparacion como medicamentos
EA201200939A1 (ru) Липиды, липидные композиции и способы их применения
WO2011014661A3 (en) Liver x receptor agonists
CY1118934T1 (el) Παρασκευη ενεργης ακρως φωσφορυλιωμενης ανθρωπινης ν-ακετυλογαλακτοζαμινης-6-σουλφατασης και χρησεις αυτης
JP2016517888A5 (da)
Okerblom et al. Human-like Cmah inactivation in mice increases running endurance and decreases muscle fatigability: implications for human evolution
HK1209633A1 (en) Compositions and methods for treating diabetes
EA201190209A1 (ru) Соединения для лечения метаболических расстройств
WO2009120919A3 (en) Fenofibrate dosage forms
WO2008070311A3 (en) Gene expression profiling of parkinson's disease
EA201391063A1 (ru) Аполипопротеин a-iv в качестве антидиабетического пептида
MX2009009171A (es) Administracion de acido 3,5-diyodotiropropionico para estimular perdida de peso y/o disminuir niveles de trigliceridos y/o para tratar sindrome metabolico.
MX2009004295A (es) Uso de un acido indazolmetoxialcanoico para reducir niveles de triglicerido, colesterol y glucosa.
EP1968561B8 (en) Treatment of diabetic nephropathy
WO2009102366A3 (en) Expression of orphan gpr64 in inflammatory diseases
WO2007056236A3 (en) Methods of treating cancer with lipid-based platinum compound formulations administered intravenously